Date: 2013-02-19
Type of information:
Compound: Kineret® (anakinra)
Company: Sobi - Swedish Orphan Biovirum (Sweden) Savient Pharmaceuticals (USA)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Rare diseases
Type agreement: promotion
Action mechanism: Kineret® (anakinra) is a recombinant protein drug approved for the treatment of rheumatoid arthritis (RA). The drug blocks the biological activity of IL-1 by binding to the interleukin-1 type 1 receptor, which is expressed in a wide variety of tissues and organs. IL-1 is a key mediator of inflammation and driver of autoinflammatory diseases in both adults and children.
Disease: rheumatoid arthritis
neonatal-onset multisystem inflammatory disease (NOMID)
Details: Sobi and Savient Pharmaceuticals have entered into an agreement for the co-promotion of Kineret® (anakinra) in the U.S. Kineret® is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active RA in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs). The drug is also indicated in the U.S. for the treatment of children and adults with the severe form of Cryopyrin-Associated Periodic Syndromes (CAPS) called Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
Savient is a specialty biopharmaceutical company that has developed and commercialized Krystexxa® (pegloticase) for the treatment of refractory chronic gout in the U.S.
Under the terms of the agreement, Sobi has granted to Savient the exclusive right to co-promote the sale of Kineret with Sobi in the U.S. Savient will market and promote Kineret beginning April 1 , 2013. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety, and regulatory activities.
Financial terms:
Latest news:
